Easterly Investment Partners LLC Sells 635,503 Shares of Quanterix Corporation $QTRX

Easterly Investment Partners LLC decreased its holdings in shares of Quanterix Corporation (NASDAQ:QTRX) by 50.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 616,681 shares of the company’s stock after selling 635,503 shares during the quarter. Easterly Investment Partners LLC’s holdings in Quanterix were worth $3,922,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Portolan Capital Management LLC raised its holdings in Quanterix by 17.2% during the 3rd quarter. Portolan Capital Management LLC now owns 4,259,851 shares of the company’s stock valued at $23,131,000 after acquiring an additional 626,229 shares during the period. Ameriprise Financial Inc. raised its holdings in Quanterix by 14.0% during the 2nd quarter. Ameriprise Financial Inc. now owns 4,236,877 shares of the company’s stock valued at $28,175,000 after acquiring an additional 521,639 shares during the period. Vanguard Group Inc. raised its holdings in Quanterix by 4.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,647,515 shares of the company’s stock valued at $14,376,000 after acquiring an additional 118,565 shares during the period. William Blair Investment Management LLC raised its holdings in Quanterix by 55.6% during the 4th quarter. William Blair Investment Management LLC now owns 2,046,449 shares of the company’s stock valued at $13,015,000 after acquiring an additional 731,169 shares during the period. Finally, Invenomic Capital Management LP raised its holdings in Quanterix by 21.7% during the 3rd quarter. Invenomic Capital Management LP now owns 1,393,005 shares of the company’s stock valued at $7,564,000 after acquiring an additional 248,101 shares during the period. Institutional investors own 86.48% of the company’s stock.

Quanterix Price Performance

Quanterix stock opened at $3.06 on Monday. Quanterix Corporation has a 52 week low of $2.39 and a 52 week high of $8.77. The business has a 50-day simple moving average of $3.25 and a 200 day simple moving average of $5.30. The stock has a market cap of $144.16 million, a price-to-earnings ratio of -1.30 and a beta of 1.14.

Quanterix (NASDAQ:QTRX) last posted its earnings results on Wednesday, May 6th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.12. Quanterix had a negative return on equity of 23.92% and a negative net margin of 71.86%.The business had revenue of $35.90 million during the quarter, compared to analysts’ expectations of $36.84 million. On average, research analysts anticipate that Quanterix Corporation will post -0.97 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on QTRX. Weiss Ratings cut shares of Quanterix from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 13th. Wall Street Zen raised shares of Quanterix from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. TD Cowen lowered their target price on shares of Quanterix from $7.00 to $4.00 and set a “hold” rating on the stock in a report on Thursday, May 7th. Finally, Canaccord Genuity Group lowered their target price on shares of Quanterix from $8.00 to $4.00 and set a “hold” rating on the stock in a report on Monday, April 20th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Quanterix presently has an average rating of “Reduce” and an average price target of $4.00.

About Quanterix

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.